User Avatar

20+ years in Tech | Project Manager | Expert in Product Launches & Strategic Communication | takashi-watanabe.eth

Counterintuitive Insights From 428 FDA Approvals That Founders Can Use to Distinguish Themselves as THE Go-To Expert in Your Space
Takashi Watanabe

So You Can Build an Unfair Advantage That Makes Competitors Irrelevant... and Land Your First 3 Strategic Partnership Deals Before Q4.

Hey there!

I dove into the numbers — 428 FDA novel approvals, financials from 4,000+ companies — and the result was blunt: startups are doing the heavy lifting. Emerging firms are now responsible for more than half of new drugs coming to clinic and increasingly keep the marketing rights. If you want a thought-leadership angle that actually moves investors and customers, this is your playbook.

You’ll walk away with one simple, high-impact tool you can use in conversations, pitches, and articles: the SMART Model — a straightforward Excel-based framework (freely published by Lumen CEO Brian Finrow in Military Medicine) that shows whether a therapeutic program can plausibly attract private capital. Use it, and you’ll sound like someone who understands money and risk — not just science.

I’ll unpack three counterintuitive lessons that founders should weaponize in their content and fundraising. Read them, repeat them, use them.

Lesson 1: Speed trumps polish — early delays cost exponentially more than late-stage failures

What’s the biggest hidden killer of investor interest? Not Phase III failure. It’s delay.

Time is money. The SMART Model makes this painfully clear: add a single year of review or funding gap and an otherwise borderline IRR collapses into negative territory. Translation? If your program sits idle for 12 months, you’ve shaved off the economics that make a VC or strategic buyer even care.

Action beats planning. Move decisions forward. Show a timeline with concrete gating and contingency plans (not just promises).

Example: programs that shave months off late-preclinical timelines (the oft-overlooked, early phase) look dramatically better on an NPV table than those that optimize only for late-stage safety signals. Why? Early-stage costs, though smaller in nominal terms, are burdened by time value and downstream attrition — which amplifies the price of delay.

(Real-world aside: the SMART Model reproduces this result — late preclinical often drives the fully burdened cost of development.)

Bottom line: Speed is a feature. Move fast, show pace, get capital excited. Repeat: speed is a feature.

Transition: But speed alone isn’t enough — you also need the right story about who pays and why.

Lesson 2: The “Big Pharma funds innovation” pitch is a myth — and that’s actually great news for founders

Most founders still pitch as if acquiring Big Pharma will be the exit. That framing is outdated.

Why it’s a fleeting belief:

  • It assumes big companies will always buy or license winners.

  • It assumes high current prices on old drugs are required to fund R&D.

  • It overweights corporate M&A as a consistent exit path.

The brutal truth (short list):

  • Big Pharma earns most revenue but creates fewer in-house discoveries.

  • Startups now originate the majority of novel drugs (50%+ in recent years; ~62% in 2020 for early-stage originators).

  • Startups increasingly keep marketing rights — from 23% in 2013 to ~75% in 2022.

So what matters? The critical factor for sustainable success is demonstrable financial resilience — the realistic probability a program attracts capital at each stage.

Reframe your narrative: don’t sell “we’ll be acquired.” Sell self-sufficiency and a path to sustainable revenue or a credible capital-raise at the next milestone. Use numbers. Use SMART Model scenarios. Show when you become fundable.

Conclude: The acquisition fairy tale is alluring — but investors reward realism. Be the founder who proves you can survive and scale.

Segue: Now let’s talk about the most common mistake founders make when talking about risk and capital.

Lesson 3: Don’t sell potential — sell calibrated, scenario-tested viability

The mistake: over-optimistic peak-sales forecasts and fuzzy market penetration maps. They sound good on slide 9 but fall apart under due diligence.

Why that limits you: investors don’t buy optimism; they buy defensible assumptions and stress-tested scenarios. The SMART Model does exactly that — it forces you to plug in phase-specific p(TS), durations, costs, and discount rates, then shows the NPV/IRR under realistic attrition.

What to do instead: present 3 scenarios (conservative, baseline, upside) and show:

  • When private capital enters,

  • How much public subsidy (if any) you'd need,

  • Which delays kill the deal.

Personal story (use this): I rewrote our messaging for a biotech founder to stop promising “blockbuster upside” and, instead, showed a conservative SMART Model run. Within weeks: better investor meetings, fewer pricing debates, and a term sheet that respected milestones (because we’d made them believable).

Powerful close: Stop selling dreams. Start selling defensible pathways.

You just learned three sharp, repeatable lessons — and a single practical tool — that will make your thought leadership actually useful to investors and partners.

Final takeaway: Use the SMART Model. Run it, publish one clear scenario in your next post, and lead with speed, realism, and capital-aware storytelling. Do that, and you’ll create an unfair advantage: credibility that converts.

Want a plug-and-play angle for your next LinkedIn post or keynote? Reply “SMART” and I’ll draft a tight, founder-friendly social post that showcases a SMART Model scenario and positions you as the realistic visionary every investor respects. DO IT — because timing matters.